Stockreport

Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union [Yahoo! Fina...

X4 Pharmaceuticals, Inc.  (XFOR) 
Last x4 pharmaceuticals, inc. earnings: 3/12 07:30 am Check Earnings Report
PDF EC approval marks a significant milestone for people living with this ultra-rare primary immunodeficiency and was granted under exceptional circumstances Norgine to l [Read more]